title: [The management of stroke in Phnom Penh, Cambodia].
abstract: Stroke ranks first among nervous pathologies in Kampuchea. It's a main cause of disability and mortality in our country. We conducted a prospective study including 100 patients hospitalized in the service of general medicine at the Calmette hospital in Phnom Penh. We analyzed the principal risk factors, clinical signs, nature of stroke, complications and markers of the vital and functional prognosis. This work shows the difficulties encountered in the initial care of stroke: delay or absence of hospitalization, cost of complementary examinations to be carried out to determine the nature and the aetiology of stroke and very low level of follow-up to ensure secondary prevention and functional rehabilitation. It can be explained in part by the socioeconomic and cultural level. Research like this one which assesses local needs for stroke prevention, treatment and rehabilitation should be conducted in developing countries to inform the planning and allocation of health care resources in order to reduce the burden of illness associated with stroke. The progressive improvement of the medical structures, and of the socioeconomic and cultural level will facilitate stroke care management.
authors.affiliation: Service de médecine A, Hôpital Calmette, Phnom Penh, Cambodge.
authors.forename: S
authors.initials: S
authors.lastname: Chan
authors.forename: S
authors.initials: S
authors.lastname: Ros
authors.forename: K Y
authors.initials: KY
authors.lastname: You
authors.forename: S
authors.initials: S
authors.lastname: Nhem
authors.forename: J Y
authors.initials: JY
authors.lastname: Salle
authors.forename: P
authors.initials: P
authors.lastname: Dudognon
authors.forename: J C
authors.initials: JC
authors.lastname: Daviet
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001241:Aspirin / Q000031:analogs & derivatives / Q000627:therapeutic use; D002545:Brain Ischemia / Q000453:epidemiology; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002160:Cambodia / Q000453:epidemiology; D002544:Cerebral Infarction / Q000453:epidemiology; D015331:Cohort Studies; D015897:Comorbidity; D003906:Developing Countries; D019468:Disease Management; D004232:Diuretics / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006297:Health Services Accessibility / Q000706:statistics & numerical data; D006761:Hospitals / Q000706:statistics & numerical data; D006801:Humans; D008239:Lysine / Q000031:analogs & derivatives / Q000627:therapeutic use; D008875:Middle Aged; D010889:Piracetam / Q000627:therapeutic use; D011379:Prognosis; D011446:Prospective Studies; D012307:Risk Factors; D012959:Socioeconomic Factors; D020521:Stroke / Q000188:drug therapy / Q000453:epidemiology*
chemical_list: D000319:Adrenergic beta-Antagonists; D002121:Calcium Channel Blockers; D004232:Diuretics; D008239:Lysine; D001241:Aspirin; C010395:acetylsalicylic acid lysinate; D010889:Piracetam